Table 1.
Baseline patient characteristics.
| Total (n = 162) |
Hospital A (n = 86) |
Hospital B (n = 76) |
P value | |
|---|---|---|---|---|
| Age (years) | 69.0 (65.0–75.3) | 69.0 (65.8–75.3) | 69.5 (64.3–77.3) | 0.971 |
| PSA (ng/mL) | 8.0 (5.2–15.2) | 6.8 (5.1–12.1) | 8.4 (5.8–20.3) | 0.033 |
| MRI protocol | < 0.001 | |||
| Multiparametric MRI | 147 (90.7) | 71 (82.6) | 76 (100) | |
| Biparametric MRI | 15 (9.3) | 15 (17.4) | 0 (0) | |
| MRI-biopsy interval (days) | 16 (9–24) | 17 (7–26) | 16 (11–21) | < 0.001 |
| Number of biopsy cores | 12 (12–15) | 15 (15–15) | 12 (12–12) | < 0.001 |
| Biopsy-confirmed prostate cancer | 94 (58.0) | 39 (45.3) | 55 (72.4) | 0.001 |
| Biopsy-confirmed clinically significant prostate cancer | 74 (45.7) | 33 (38.4) | 41 (53.9) | 0.058 |
| Highest Gleason grade group* | 0.253 | |||
| 1 | 20 (21.3) | 6 (15.4) | 14 (25.5) | |
| 2 | 29 (30.9) | 11 (28.2) | 18 (32.7) | |
| 3 | 24 (25.5) | 13 (33.3) | 11 (20.0) | |
| 4 | 13 (13.8) | 5 (12.8) | 8 (14.5) | |
| 5 | 8 (8.5) | 4 (10.3) | 4 (7.3) | |
| Radical prostatectomy | 32 (19.8) | 10 (11.6) | 22 (28.9) | 0.006 |
| Positive EPE† | 10 (31.2) | 3 (30.0) | 7 (31.8) | 0.919 |
PSA, prostate-specific antigen; PI-RADS, Prostate Imaging Reporting and Data System; EPE, extraprostatic extension.
The data are presented as medians with interquartile ranges in parentheses or as frequencies (proportions).
* Proportion among patients with biopsy-confirmed prostate cancer.
† Proportion among patients who underwent prostatectomy.